Generic Competition, Price and Access to Medicines: The case of antiretrovirals in Uganda

Kamal-Yanni, Mohga

dc.contributor.author	Kamal-Yanni, Mohga	*
dc.date.accessioned	2010-11-03T12:15:00Z	en
dc.date.available	2010-11-03T12:15:00Z	en
dc.date.issued	2002-07-10
dc.identifier.isbn	978-1-84814-409-5
dc.identifier.uri	http://hdl.handle.net/10546/114502
dc.description	Access to treatment is a key part of national strategies to combat HIV/AIDS. Antiretrovirals can increase the length and quality of life, and the productivity of patients. Research in Uganda shows that poor people will use ARVs if the price is right and if a delivery system is place. It also shows that the price of brand-name drugs fell significantly only when generics entered the market. Generic competition, the use of the public-health safeguards in the TRIPS Agreement, and urgent funding for health-service delivery are essential parts of the fight against HIV/AIDS in developing countries such as Uganda.	en_US
dc.format.extent	14	en_US
dc.format.mimetype	PDF	en_US
dc.language.iso	English	en_US
dc.language.iso	Spanish	en_US
dc.publisher	Oxfam International	en_US
dc.relation.url	https://policy-practice.oxfam.org.uk/publications/generic-competition-price-and-access-to-medicines-the-case-of-antiretrovirals-i-114502
dc.subject	Health
dc.title	Generic Competition, Price and Access to Medicines: The case of antiretrovirals in Uganda	en_US
dc.type	Briefing paper	en_US
oxfam.signoff.status	For public use. Can be shared outside Oxfam.	en_US
oxfam.subject.country	Uganda	en_US
oxfam.subject.keyword	HIV and AIDS	en_US
oxfam.subject.keyword	Access to medicines	en_US
dc.year.issuedate	2002	en_US
refterms.dateFOA	2018-08-20T11:13:45Z